A promising new inotrope: Levosimendan;Umut verici yeni bir inotropik ajan: Levosimendan

Anadolu Kardiyoloji Dergisi

Volumn 10, Issue 2, 2010, Pages 176-182

  Fotbolcu, Hakan ^a   Duman, Dursun ^b  

^a MEDICAL PARK HOSPITAL   (Turkey)

^b GATA HAYDARPASA TRAINING HOSPITAL   (Turkey)

Author keywords

Clinical trials; Heart failure; Levosimendan; Positive inotropic agents

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CATECHOLAMINE DERIVATIVE; DIURETIC AGENT; DOBUTAMINE; INOTROPIC AGENT; LEVOSIMENDAN; PLACEBO; VASODILATOR AGENT; CALCIUM; CARDIOTONIC AGENT; HYDRAZONE DERIVATIVE; POTASSIUM CHANNEL; PYRIDAZINE DERIVATIVE; SIMENDAN;

ACUTE CORONARY SYNDROME; ACUTE HEART FAILURE; CARDIOGENIC SHOCK; CHILD CARE; CLINICAL TRIAL; CONGENITAL HEART DISEASE; CONGESTIVE HEART FAILURE; CONTINUOUS INFUSION; DIZZINESS; DOSE RESPONSE; DRUG CLEARANCE; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG HALF LIFE; DRUG INFUSION; DRUG MECHANISM; DRUG MEGADOSE; DRUG RESEARCH; DRUG SAFETY; DRUG TOLERABILITY; DRUG USE; FOLLOW UP; HEADACHE; HEART ATRIUM FIBRILLATION; HEART FAILURE; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HEART RIGHT VENTRICLE FAILURE; HEART SURGERY; HEART VENTRICLE ARRHYTHMIA; HEART VENTRICLE EXTRASYSTOLE; HEART VENTRICLE TACHYCARDIA; HUMAN; HYPOKALEMIA; HYPOTENSION; ISCHEMIA; ISCHEMIC HEART DISEASE; KIDNEY FAILURE; LOADING DRUG DOSE; NAUSEA; NONHUMAN; PERCUTANEOUS CORONARY INTERVENTION; PERIOPERATIVE PERIOD; PULMONARY HYPERTENSION; REVIEW; SEPTIC SHOCK; SINGLE DRUG DOSE; SYSTOLIC DYSFUNCTION; TRANSLUMINAL CORONARY ANGIOPLASTY; DRUG EFFECT; HEART OUTPUT; HEART VENTRICLE FUNCTION; METABOLISM; PHYSIOLOGY; TREATMENT OUTCOME;

CALCIUM; CARDIAC OUTPUT; CARDIOTONIC AGENTS; HEART FAILURE; HUMANS; HYDRAZONES; POTASSIUM CHANNELS; PYRIDAZINES; TREATMENT OUTCOME; VENTRICULAR DYSFUNCTION;

EID: 77952512779     PISSN: 13028723     EISSN: None     Source Type: Journal    
DOI: 10.5152/akd.2010.045     Document Type: Review

References (61)

1. Krum H, Liew D. New and emerging drug therapies for the management of acute heart failure. Intern Med J 2003; 33: 515-20.
2. Nieminen MS, Harjola VP. Definition and epidemiology of acute heart failure syndromes. Am J Cardiol 2005; 96 (Suppl 6A): 5G-10G.
3. Thackray S, Easthaugh J, Freemantle N, Cleland JG. The effectiveness and relative effectiveness of intravenous inotropic drugs acting through the adrenergic pathway in patients with heart failure-a meta regression analysis. Eur J Heart Fail 2002; 4: 515-29.
4. Packer M. The search for the ideal positive inotropic agent. N Engl J Med 1993; 329: 201-2.
5. Pagel PS, Harkin CP, Hettrick DA, Warltier DC. Levosimendan (OR- 1259), a myofilament calcium sensitizer, enhances myocardial contractility but does not alter isovolumic relaxation in conscious and anesthetized dogs. Anesthesiology 1994; 81: 974-87.
6. Udvary E, Papp JG, Végh A. Cardiovascular effects of the calcium sensitizer, levosimendan, in heart failure induced by rapid pacing in the presence of aortic constriction. Br J Pharmacol 1995; 114: 656-61.
7. Kass DA, Solaro RJ. Mechanisms and use of calcium-sensitizing agents in the failing heart. Circulation 2006; 113: 305-15.
8. Hasenfuss G, Pieske B, Castell M, Kretschmann B, Maier LS, Just H. Influence of the novel inotropic agent levosimendan on isometric tension and calcium cycling in failing human myocardium. Circulation 1998; 98: 2141-7.
9. Ukkonen H, Saraste M, Akkila J, Knuuti MJ, Lehikoinen P, Nagren K, et al. Myocardial efficiency during calcium sensitization with levosimendan: a noninvasive study with positron emission tomography and echocardiography in healthy volunteers. Clin Pharmacol Ther 1997; 61: 596-607.
10. Yokoshiki H, Katsube Y, Sunagawa M, Sperelakis N. Levosimendan, a novel Ca 2 sensitizer, activates the glibenclamide-sensitive K-channel in rat arterial myocytes. Eur J Pharmacol 1997; 333: 249-59.
11. Kaheinen P, Pollesello P, Levijoki J, Haikala H. Levosimendan increases diastolic coronary flow in isolated guinea-pig heart by opening ATP-sensitive potassium channels. J Cardiovasc Pharmacol 2001; 37: 367-74.
12. Harkin CP, Pagel PS, Tessmer JP, Warltier DC. Systemic and coronary hemodynamic actions and left ventricular functional effects of levosimendan in conscious dogs. J Cardiovasc Pharmacol 1995; 26: 179-88.
13. Michaels AD, McKeown B, Kostal M, Vakharia KT, Jordan MV, Gerber IL, et al. Effects of intravenous levosimendan on human coronary vasomotor regulation, left ventricular wall stress and myocardial oxygen uptake. Circulation 2005; 111: 1504-9.
14. Yokoshiki H, Katsube Y, Sunagawa M, Sperelakis N. The novel calcium sensitizer levosimendan activates the ATP-sensitive K+ channel in rat ventricular cells. J Pharmacol Exp Ther 1997; 283: 375-83.
15. Maytin M, Colucci WS. Cardioprotection-a new paradigm in the acute management of decompensated heart failure. Am J Cardiol 2005; 96: 26G-31G.
16. Kivikko M, Antila S, Eha J, Lehtonen L, Pentikainen PJ. Pharmacokinetics of levosimendan and its metabolites during and after a 24-hour continuous infusion in patients with severe heart failure. Int J Clin Pharmacol Ther 2002; 40: 465-71.
17. Kivikko M, Lehtonen L, Colucci WS. Sustained hemodynamic effects of intravenous levosimendan. Circulation 2003;107: 81-6.
18. Puttonen J, Kantele S, Kivikko M, Hakkinen S, Harjola VP, Koskinen P, et al. Effect of severe renal failure and haemodialysis on the pharmacokinetics of levosimendan and its metabolites. Clin Pharmacokinet 2007; 46: 235-46.
19. Follath F, Cleland JG, Just H, Papp JG, Scholz H, Peuhkurinen K, et al. Efficacy and safety of intravenous levosimendan compared with dobutamine in severe low-output heart failure (the LIDO study): A randomized double-blind trial. Lancet 2002; 360: 196-202.
20. Zairis MN, Apostolatos C, Anastassiadis F, Kouris N, Grassos H. Comparison of the effect of levosimendan,or dobutamine or placebo in chronic low output decompensated heart failure. Calcium Sensitizer or Inotrope or NOne in low output heart failure (CASINO) study. Program and abstracts of the European Society of Cardiology, Heart Failure Update; 2004 June 12-15; Wroclaw, Poland: p.273.
21. Moiseyev VS, Poder P, Andrejevs N, Ruda MY, Golikov AP, Lazebnik LB, et al. Safety and efficacy of a novel calcium sensitizer, levosimendan, in patients with left ventricular failure due to an acute myocardial infarction: a randomized, placebo-controlled, doubleblind study (RUSSLAN). Eur Heart J 2002; 23: 1422-32.
22. Cleland JG, Freemantle N, Coletta AP, Clark AL. Clinical trials update from the American Heart Association: REPAIR-AMI, ASTAMI, JELIS, MEGA, REVIVE-II, SURVIVE, and PROACTIVE. Eur J Heart Fail 2006; 8: 105-10.
23. Packer M. The Randomized multicenter EValuation of Intravenous leVosimendan Efficacy-2 (REVIVE-2) trial. Late-breaking Clinical Trials. American Heart Association, Annual Scientific Session; 2005 Nov 13-16: Dallas, TX.
24. Mebazaa A, Cohen-Solal A, Kleber F. Study design of a mortality trial with intravenous levosimendan (the SURVIVE study) in patients with acutely decompensated heart failure. (Abstract). Crit Care 2004; 8 Suppl 1: 87.
25. Mebazaa A. The SURVival of patients with acute heart failure in need of intraVEnous inotropic support (SURVIVE) trial. Latebreaking Clinical Trials. American Heart Association, Annual Scientific Session; 2005 Nov 13-16: Dallas, TX.
26. Cohen-Solal A, Logeart D, Huang B, Cai D, Nieminen MS, Mebazaa A. Lowered B-type natriuretic peptide in response to levosimendan or dobutamine treatment is associated with improved survival in patients with severe acutely decompensated heart failure. J Am Coll Cardiol 2009; 53: 2343-8.
27. Mebazaa A, Nieminen MS, Filippatos GS, Cleland JG, Salon JE, Thakkar R, et al. Levosimendan vs. dobutamine: outcomes for acute heart failure patients on beta-blockers in SURVIVE. Eur J Heart Fail 2009; 11: 304-11.
28. Duman D, Palit F, Şimşek E, Karadaǧ B. Atalay S, Akdoǧan F, et al. Effects of levosimendan versus dobutamine on left atrial function in decompensated heart failure. Eur Heart J 2008;29 (Abstract Supplement): 303.
29. Duman D, Palit F, Simsek E, Karadag B, Atalay S. Effects of levosimendan versus dobutamine on left atrial function in decompensated heart failure. Can J Cardiol 2009; 25: e353-6.
30. Barbier P, Solomon SB, Schiller NB, Glantz SA. Left atrial relaxation and left ventricular systolic function determine left atrial reservoir function. Circulation 1999; 100: 427-36.
31. Matsuda Y, Toma Y, Ogawa H, Matsuzaki M, Katayama K, Fujii T, et al. Importance of left atrial function in patients with myocardial infarction. Circulation 1983; 67: 566-71.
32. Duman D, Palit F, Şimşek E, Yildiz O. Comparative effects of levosimendan and dobutamine on left ventricular diastolic function and brain natriuretic peptide in patients with decompensated advanced heart failure European Heart Journal 2009; 30 (Abstract Supplement): 348.
33. Nieminen MS, Akkila J, Hasenfuss G, Kleber FX, Lehtonen LA, Mitrovic V, et al. Hemodynamic and neurohumoral effects of continuous infusion of levosimendan in patients with congestive heart failure. J Am Coll Cardiol 2000; 36: 1903-12.
34. Slawsky MT, Colucci WS, Gottlieb SS, Greenberg BH, Haeusslein E, Hare J, et al. Acute hemodynamic and clinical effects of levosimendan in patients with severe heart failure. Study Investigators. Circulation 2000; 102: 2222-7.
35. Dickstein K, Cohen-Solal A, Filippatos G, McMurray JJ, Ponikowski P, Poole-Wilson PA, et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). Eur Heart J 2008; 29: 2388-442.
36. Hunt SA, Abraham WT, Chin MH, Feldman AM, Francis GS, Ganiats TG, et al. Focused update incorporated into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults. A Report of the American College of Cardiology Foundation/ American Heart Association Task Force on Practice Guidelines Developed in Collaboration With the International Society for Heart and Lung Transplantation. J Am Coll Cardiol 2009; 53: e1-e90.
37. Caldicott LD, Hawley K, Heppel R, Woodmansey PA, Channer KS. Intravenous enoximone or dobutamine for severe heart failure after acute myocardial infarction: a randomized double-blind trial. Eur Heart J 1993; 14: 696-700.
38. Gillespie TA, Ambos HD, Sobel BE, Roberts R. Effects of dobutamine in patients with acute myocardial infarction. Am J Cardiol 1977; 39: 588-94.
39. Nieminen MS, Sandell EP. Considerations on the efficacy and safety of levosimendan in ischemic heart failure. Ital Heart J 2003;4 Suppl 2: 39S-44S.
40. Sonntag S, Sundberg S, Lehtonen L, Kleber FX. The calcium sensitizer levosimendan improves the function of stunned myocardium after percutaneous transluminal coronary angioplasty in acute myocardial ischemia. J Am Coll Cardiol 2004; 43: 2177-82.
41. Franco F, Monteiro P, Correia J. Levosimendan is safe and effective in patients with severe low cardiac output heart failure and critical hypotension. (Abstract). J Am Coll Cardiol 2004; 43: 191A.
42. McLean A, Huang S, Stewart D, Nalos M, Tang B. Efficacy of levosimendan in shock. (Abstract). Crit Care 2004; 6: P83.
43. Samimi-Fard S, Garci-Gonziez MJ, Domiguez-Rodriuez A, Abreu-Gonzaez P. Effects of levosimendan versus dobutamine on long-term survival of patients with cardiogenic shock after primary coronary angioplasty. Int J Cardiol 2008; 127: 284-7.
44. Tsagalou EP, Kanakakis J, Anastasiou-Nana MI, Drakos SG, Ntalianis AS, Malliaras K, et al. Hemodynamic effects of levosimendan in acute myocardial infarction complicated by cardiogenic shock and high systemic vascular resistance. Acute Card Care 2009;11: 99-106.
45. Scheiermann P, Ahluwalia D, Hoegl S, Dolfen A, Revermann M, Zwissler B, et al. Effects of intravenous and inhaled levosimendan in severe rodent sepsis. Intensive Care Med 2009; 35: 1412-9.
46. Fries M, Ince C, Rossaint R, Bleilevens C, Bickenbach J, Rex S, et al. Levosimendan but not norepinephrine improves microvascular oxygenation during experimental septic shock. Crit Care Med 2008; 36: 1886-91.
47. Zangrillo A, Biondi-Zoccai G, Mizzi A, Bruno G, Bignami E, Gerli C, et al. Levosimendan reduces cardiac troponin release after cardiac surgery: a meta-analysis of randomized controlled studies. J Cardiothorac Vasc Anesth 2009;23: 474-8.
48. Aksun M, Karahan N, Adanir T, Aran G, Yetkin U, Oztuk T, et al. Timing of levosimendan in cardiac surgery. Anadolu Kardiyol Derg 2009; 9: 223-30.
49. Braun JP, Schneider M, Kastrup M, Liu J. Treatment of acute heart failure in an infant after cardiac surgery using levosimendan. Eur J Cardiothorac Surg 2004; 26: 228-30.
50. Turanlahti M, Boldt T, Palkama T, Antila S, Lehtonen L, Pesonen E. Pharmacokinetics of levosimendan in pediatric patients evaluated for cardiac surgery. Pediatr Crit Care Med 2004; 5: 457-62.
51. Duygu H, Özerkan F, Zoghi M, Nalbantgil S, Yildiz A, Akilli A, et al. Effect of levosimendan on right ventricular systolic and diastolic functions in patients with ischaemic heart failure. Int J Clin Pract 2008; 62: 228-33.
52. Kaşikioǧlu HA, Uyarel H, Tartan Z, Kaşikioǧlu E, Özturk R, Cam N. Do calcium sensitizers affect right ventricular functions in patients with chronic heart failure? Int J Cardiol 2007; 118: 246-8.
53. Cavuşoǧlu Y, Beyaztaş A, Birdane A, Ata N. Levosimendan is not effective in reducing pulmonary pressures in patients with idiopathic pulmonary arterial hypertension: report of two cases. J Cardiovasc Med (Hagerstown) 2009; 10: 503-7.
54. Hosenpud JD. Levosimendan, a novel myofilament calcium sensitizer, allows weaning of parenteral inotropic therapy in patients with severe congestive heart failure. Am J Cardiol 1999; 83 (Suppl 2): 9-11.
55. Harjola VP, Peuhkurinen K, Nieminen MS, Niemela M, Sundberg S. Oral levosimendan improves cardiac function and hemodynamics in patients with severe congestive heart failure. Am J Cardiol 1999; 83 (Suppl 1): 4-8.
56. Nieminen MS, Cleland JG, Eha J, Belenkov Y, Kivikko M, Poer P, et al. Oral levosimendan in patients with severe chronic heart failure -the PERSIST study. Eur J Heart Fail 2008; 10: 1246-54.
57. Mebazaa A, Erhardt L. Levosimendan: a new dual-action drug in the treatment of acute heart failure. Int J Clin Pract 2003; 57: 410-6.
58. Mebazaa A, Nieminen MS, Packer M, Cohen-Solal A, Kleber FX, Pocock SJ, et al. SURVIVE Investigators. Levosimendan vs dobutamine for patients with acute decompensated heart failure: The SURVIVE Randomized Trial. JAMA 2007; 297: 1883-91.
59. Duman D, Palit F, Şimşek E, Yildiz O. Effects of levosimendan versus dobutamine on ventricular arrhythmias and autonomic indexes in patients with advanced heart failure. Eur Heart J 2009; 30 (Abstract Supplement): 1031.
60. Yilmaz MB, Yalta K, Yontar C, Karadaş F, Erdem A, Turgut OO, et al. Levosimendan improves renal function in patients with acute decompensated heart failure: comparison with dobutamine. Cardiovasc Drugs Ther 2007; 21: 431-5.
61. Kaptan K, Erinc K, Ifran A, Yildirim V, Uzun M, Beyan C, et al. Levosimendan has an inhibitory effect on platelet function. Am J Hematol 2008; 83: 46-9.